Patents Assigned to AVIR Green Hills Biotechnology
-
Publication number: 20130183740Abstract: The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus which comprises at least one amino acid modification within the N-terminal cyto plasmic region of the NA protein.Type: ApplicationFiled: June 6, 2011Publication date: July 18, 2013Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AGInventors: Thomas Muster, Andrej Egorov, Markus Wolschek
-
Patent number: 8288145Abstract: The use of macrolide polyene antibiotics or derivatives or analogues thereof as culture supplement for the propagation of virus is described. Further pharmaceutical compositions comprising a virus and a macrolide polyene antibiotic or a derivative or analogue thereof and methods for using of macrolide polyene antibiotics for transfection and infection of cells as well as the use of macrolide polyene antibiotics for the isolation of virus from clinical samples are disclosed.Type: GrantFiled: October 11, 2007Date of Patent: October 16, 2012Assignee: AVIR Green Hills BiotechnologyInventors: Elisabeth Röthl, Andrej Egorov
-
Publication number: 20120237527Abstract: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.Type: ApplicationFiled: April 19, 2012Publication date: September 20, 2012Applicant: Avir Green Hills Biotechnology Research Development Trade AGInventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster
-
Publication number: 20110268764Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.Type: ApplicationFiled: May 3, 2011Publication date: November 3, 2011Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AGInventors: Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
-
Publication number: 20110262481Abstract: The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No.1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.Type: ApplicationFiled: December 18, 2009Publication date: October 27, 2011Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AGInventors: Thomas Muster, Markus Wolschek, Andrej Egorov, Elisabeth Roethl, Julia Romanova, Michael Bergmann
-
Publication number: 20110250587Abstract: The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus.Type: ApplicationFiled: December 3, 2009Publication date: October 13, 2011Applicant: Avir Green Hills Biotechnology Research Development Trade AGInventors: Thomas Muster, Andrej Egorov, Markus Wolschek
-
Publication number: 20110223199Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.Type: ApplicationFiled: November 25, 2009Publication date: September 15, 2011Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AGInventors: Julia Romanova, Andrej Egorov, Brigitte Krenn, Markus Wolschek, Sabine Nakowitsch
-
Patent number: 8008460Abstract: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.Type: GrantFiled: October 30, 2008Date of Patent: August 30, 2011Assignee: Avir Green Hills Biotechnology Research Development Trade AGInventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster
-
Publication number: 20100184191Abstract: The present invention provides a method for generating negative-strand, segmented RNA viruses using linear expression constructs in the presence of helper virus.Type: ApplicationFiled: December 3, 2009Publication date: July 22, 2010Applicant: AVIR Green Hills Biotechnology Research Development Trade AGInventors: Thomas MUSTER, Andrej EGOROV, Markus WOLSCHEK
-
Publication number: 20100172934Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.Type: ApplicationFiled: November 25, 2009Publication date: July 8, 2010Applicant: AVIR Green Hills Biotechnology Research Developmen Trade AGInventors: Brigitte KRENN, Markus WOLSCHEK, Julia ROMANOVA, Andrej EGOROV, Sabine Nakowitsch
-
Publication number: 20100136518Abstract: The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.Type: ApplicationFiled: May 23, 2008Publication date: June 3, 2010Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENInventors: Johannes Humer, Bernd Mayer, Thomas Muster, Andrea Waltenberger
-
Publication number: 20100136052Abstract: The present invention covers a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. Further the use of the virus as vector for expression of various proteins like chemokines, cytokines or antigenic structures is covered, methods for producing virus particles using said virus vector as well as its use for production of vaccines. Also a fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is covered.Type: ApplicationFiled: June 26, 2008Publication date: June 3, 2010Applicant: AVIR Green Hills Biotechnology Research Development Trade AGInventors: Markus Wolschek, Andrej Egorov, Michael Bergmann, Thomas Muster, Christian Kittel
-
Publication number: 20100129399Abstract: The present invention provides a linear expression construct free of any conventional amplification and/or selection sequences comprising an RNA polymerase I (polI) promoter and a polI termination signal, inserted between a RNA polymerase II (polII) promoter and a polyadenylation signal useful for the expression of segments of viral RNA, preferably influenza viruses. The inventive construct is useful for efficient and fast production of viral particles, especially for producing vaccine formulations for the treatment of epidemic and/or pandemic diseases.Type: ApplicationFiled: June 26, 2008Publication date: May 27, 2010Applicant: AVIR Green Hills Biotechnology Research Development Trade AGInventors: Markus Wolschek, Andrej Egorov, Michael Bergmann, Thomas Muster, Christian Kittel
-
Publication number: 20100003221Abstract: The use of macrolide polyene antibiotics or derivatives or analogues thereof as culture supplement for the propagation of virus is described. Further pharmaceutical compositions comprising a virus and a macrolide polyene antibiotic or a derivative or analogue thereof and methods for using of macrolide polyene antibiotics for transfection and infection of cells as well as the use of macrolide poylene antibiotics for the isolation of virus from clinical samples are disclosed.Type: ApplicationFiled: October 11, 2007Publication date: January 7, 2010Applicant: AVIR Green Hills Biotechnology Research Development Trade AGInventors: Elisabeth Röthl, Andrej Egorov
-
Publication number: 20090130129Abstract: The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines.Type: ApplicationFiled: May 11, 2006Publication date: May 21, 2009Applicant: Avir Green Hills Biotechnology Research Development Trade AGInventors: Bernd Mayer, Johannes Humer, Thomas Muster, Andrea Waltenberger
-
Publication number: 20090123495Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.Type: ApplicationFiled: August 8, 2006Publication date: May 14, 2009Applicant: Avir Green Hills Biotechnology Research Development Trade AGInventors: Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
-
Patent number: 7510862Abstract: Described is a polynucleotide molecule being a fragment of a polynucleotide sequence of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence selected from the group consisting of (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 1, (b) a sequence which hybridises under stringent conditions with a nucleotide sequence according to said SEQ ID No 1, (c) a sequence which differs from said sequences (a) or (b) due to degeneration of the genetic code and (d) a sequence comprising sequences inserted into vectors pCR4-Topo and deposited as “MERV-env”, “MERV-gag”, “MERV-prt” and “MERV-pol” at the DSMZ on 26 Sep. 2001 or fragments thereof.Type: GrantFiled: September 27, 2002Date of Patent: March 31, 2009Assignee: Avir Green Hills Biotechnology Research Development Trade AGInventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster
-
Publication number: 20080008717Abstract: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.Type: ApplicationFiled: July 25, 2007Publication date: January 10, 2008Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH AGInventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster
-
Patent number: 7282599Abstract: The invention discloses a use of dithiocarbamate compounds having the structural formula R1R2NCS2H, in which R1 and R2, independently of each other, represent a straight or branched C1-C4 alkyl, or, with the nitrogen atom, form an aliphatic ring with 4 to 6 C atoms, in which R1, R2, or the aliphatic ring is optionally substituted with one or more substituents selected from OH, NO2, NH2, COOH, SH, F, Cl, Br, I, methyl or ethyl, and oxidized forms of these compounds, in particular dimers thereof, as well as pharmaceutically acceptable salts thereof, to prepare an agent for treating or preventing an infection by RNA viruses which attack the respiratory tract and cause disease there.Type: GrantFiled: July 15, 2002Date of Patent: October 16, 2007Assignee: Avir Green Hills Biotechnology Research Devlopment Trade AGInventors: Elisabeth Gaudernak, Andreas Grassauer, Ernst Küchler, Thomas Muster, Joachim Seipelt